Clinical Trial

Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

Study acronym: LCCS
Completed
View on ClinicalTrials.gov →
Summary
This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.
Protocol Amendment History 4 changes
critical Trial completed 2026-07-03
notable Enrollment reduced: 300 -> 237 participants 2026-07-03
notable Primary completion moved earlier: 2026-02-28 -> 2025-12-31 2026-07-03
minor Completion pushed: 2026-04-16 -> 2026-06-30 2026-07-03
Trial Details
NCT Number NCT07005947
Lead Sponsor CND Life Sciences
Conditions Long COVID-19, Acute COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS), Diabetic Neuropathy
Enrollment 237 participants
Start Date 2023-11-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02